Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Practice Point
Nature Reviews Clinical Oncology 2, 70–71 (1 February 2005) | doi:10.1038/ncponc0076
Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?
&
Abstract
Petrylak DP et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513–1520 Synopsis Background Mitoxantrone (Novantrone, OSI) plus corticosteroids relieves pain, but does not prolong survival, of men with metastatic androgen-independent prostate cancer.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
